COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

See Prescribing Information

Proactively help protect against multiple myelosuppressive consequences

COSELA is the first and only myeloprotection therapy